Trapidil is an inhibitor of PDGF-induced activity and an antiplatelet agent.1,2 It inhibits PDGF-induced proliferation of U251MG glioma cells and isolated rat aortic smooth muscle cells in a concentration-dependent manner. Trapidil (1 mM) inhibits platelet aggregation induced by ADP, arachidonic acid , or U-46619 in washed isolated human platelets.3 It reduces increases in intimal thickness and prevents restenosis induced by balloon angioplasty in rabbits fed a high-cholesterol diet when administered at a dose of 30 mg/kg.4
1.Kuratsu, J., and Ushio, Y.Antiproliferative effect of trapidil, a platelet-derived growth factor antagonist, on a glioma cell line in vitroJ. Neurosurg.73(3)436-440(1990) 2.Hoshiya, M., and Awazu, M.Trapidil inhibits platelet-derived growth factor-stimulated mitogen-activated protein kinase cascadeHypertension31(2)665-671(1998) 3.Mazurov, A.V., Yu, M., Leytin, V.L., et al.Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidilFEBS Lett.172(2)167-171(1984) 4.Liu, M.W., Roubin, G.S., Robinson, K.A., et al.Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbitCirculation81(3)1089-1093(1990)